Navigation Links
Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
Date:8/19/2007

Oncomine and Oncomine Concepts Map Integral in Expression and Association

Analyses

ANN ARBOR, Mich., Aug. 2 /PRNewswire/ -- Building on an earlier study that used Oncomine(TM) to identify ETS-fusion proteins in prostate cancer (Science, Oct 28 2005), Tomlins et al. today report the identification of four additional classes of ETS rearrangements in prostate cancer, each of which activates ETV1 by a different genetic mechanism (Nature, Aug 2 2007).

(Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO )

Tomlins et al. queried the Oncomine database to determine the tissue specificity of three of the new fusion gene partners, demonstrating that two new partners are prostate cancer specific while the third partner is a generally over-expressed 'house-keeping' gene. In addition, Oncomine Concepts Map was applied to test for similarities between the set of genes regulated by ETV1 with sets of genes related to other biological concepts. This analysis revealed a clear association between ETV1 activation and cellular invasion, a hallmark of cancer.

Oncomine, a dynamic repository that combines rich data, sophisticated analysis, and responsive user interface, empowers oncology research by bringing data analysis tools to a large cancer gene expression database, which includes data from 20,000+ microarray experiments curated from 300+ independent studies. Oncomine Concepts Map, an extension of Oncomine, is a compilation of nearly 8,000 Oncomine cancer gene signatures together with 11,500 gene, protein, drug, and pathway signatures collected from the literature and other public sources.

"This study marks an important advance in our understanding of the molecular basis of prostate cancer. Oncomine again proved invaluable in examining the expression of genes in cancer, and in this case aided in the characterization of new sub-types of prostate cancer," said Dan Rhodes, Ph.D., co-founder and Chief Science Officer of Compendia Bioscience. "The authors went on to show that one of the new subtypes is unlikely to respond to conventional anti-androgen therapy, and another may be adversely affected by standard therapies. This strongly suggests that using this type of molecular information to distinguish patient populations will have important clinical implications."

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes.

About Oncomine(TM)

Oncomine(TM) combines a rapidly growing compendium of 20,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates rapid and reliable biomarker and therapeutic target discovery, validation, and prioritization.

About Oncomine(TM) Concepts Map

Oncomine Concepts Map is licensed to commercial users as part of the Oncomine Concepts Edition and the Oncomine Enterprise Edition. Visit http://www.compendiabio.com for more information. An academic preview edition is available to academic and non-profit researchers at http://www.oncomine.org.


'/>"/>
SOURCE Compendia Bioscience, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
2. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
3. Protox Announces Positive Clinical Data from Prostate Cancer Study
4. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
5. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
6. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
7. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
8. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
9. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
10. Quest PharmaTechs Prostate Cancer Program Update
11. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: PRGO) ... Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide ... Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), ... symptomatic relief of cough in adults and children 6 years ... ending January 2017 were approximately $16 million.   ...
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and Rest ... through 2022. Also, a six-year historic analysis is provided for these markets. ...
(Date:2/17/2017)... MIAMI , Feb. 17, 2017  In partnership ... Friends for Good Health , The Jack ... container filled with millions of dollars, worth of medicine ... Haiti . IHI is a non-profit dedicated to ... IHI is extremely active in Haiti ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... 2017 , ... Braun Industries will be participating as an exhibitor at EMS ... place February 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center in ... new ambulances on display. , “JEMS is a leader in EMS news ...
(Date:2/18/2017)... Massachusetts (PRWEB) , ... February 17, 2017 , ... ... the leading source of disruptive innovation in the industry, according to the recent ... Reports are based on surveys of the NEJM Catalyst Insights Council, a qualified ...
(Date:2/18/2017)... ... February 18, 2017 , ... ... the latest information and contact points to easily connect elderly veterans of America's ... living, and elder-care funding. It also conveys material on this year's increase in ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... its educational assistance management solution to the exhibit floor for the 2017 ... Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
Breaking Medicine News(10 mins):